Effects of endoscopic variceal sclerotherapy using GT XIII on blood coagulation tests and the renal kallikrein-kinin system.
Forty-six sclerotherapy sessions were performed on liver cirrhotics with high-risk esophageal varices using GT XIII, a sclerosant composed of gelatin, thrombin and coagulation factor XIII. GT XIII was effective for the prevention of temporary symptoms and transient hypotension observed in 55 sclerotherapy sessions using thrombin. In 42 (91%) sessions, patients underwent sclerotherapy with no symptoms, and in the other four (9%) sessions, only slight symptoms of general fatigue and headache were observed. Changes in the mean arterial pressure were significantly smaller in sessions using GT XIII than in those using thrombin (-12.3 +/- 13.6 vs. -26.8 +/- 20.7 mmHg, P less than 0.01). Changes in coagulation tests, similar to those of disseminated intravascular coagulation (DIC), were also reduced in sessions using GT XIII. Urinary kallikrein and kinin excretion significantly increased after the procedure (P less than 0.01), indicating activation of the renal kallikrein-kinin system. Increases in urinary kallikrein and kinin excretion showed a significant relationship with the consumed plasma fibrinogen levels (r = -0.51, P less than 0.01 and r = -0.58, P less than 0.01, respectively), and it was suggested that activation of the glandular kallikrein-kinin system caused by abrupt DIC-like changes in the hemostatic system might play a role in manifestations of temporary complications occurring with the use of hemostatic agents containing thrombin.
Yuki
N
N
Department of Internal Medicine, Osaka Police Hospital, Japan.
Kubo
M
M
Noro
Y
Y
Hayashi
N
N
Fusamoto
H
H
Ito
A
A
Masuzawa
M
M
Kamada
T
T
D001777:Blood Coagulation / Q000187:drug effects*; D004932:Esophageal and Gastric Varices / Q000209:etiology / Q000628:therapy*; D005176:Factor XIII / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016234:Kallikrein-Kinin System / Q000187:drug effects*; D007668:Kidney / Q000201:enzymology; D008103:Liver Cirrhosis / Q000150:complications; D008297:Male; D008875:Middle Aged; D012597:Sclerosing Solutions / Q000627:therapeutic use*; D015911:Sclerotherapy; D013917:Thrombin / Q000627:therapeutic use*
C050909:G-T-XIII; D012597:Sclerosing Solutions; D005176:Factor XIII; D013917:Thrombin